Interleukin-6 (IL-6) Inhibitors Therapeutics Pipeline to Witness Many Collaborations in Coming Years

IL-6 inhibitors currently exhibits a growing pipeline with approximately 18 active drug candidates, P&S Market Research

The study analyzed that the IL-6 inhibitors therapeutics pipeline comprises approximately 18 active drug candidates in different stages of development. Interleukin-6 inhibitors acts on the IL-6 receptor. IL-6 receptors belong to a group of cytokine receptors that are expressed by leukocytes and plays an important role in the functioning of the immune system. It has a characteristic role in systemic inflammation in numerous disease conditions, including rheumatoid arthritis, and psoriatic arthritis. 

According to the research findings, most of the drug candidates of the IL-16 inhibitors are being developed as the monoclonal antibody.

The positive clinical results from IL-6 inhibitors drug candidates have been driving the pipeline growth. GlaxoSmithKline plc presented results from two pivotal Phase III studies (NCT01606761; NCT02019472) evaluating subcutaneous sirukumab. In both the studies, sirukumab met the primary endpoint showing significant improvement in the signs and symptoms of moderately to severely active rheumatoid arthritis compared to placebo. 

Download Report Sample Copy at: https://www.psmarketresearch.com/market-analysis/interleukin-6-inhibitors-therapeutics-pipeline/report-sample

In January 2017, Tiziana Life Sciences plc acquired an exclusive world-wide license for NI-1201, a fully human anti-IL-6R monoclonal antibody (mAb), from Novimmune SA. In exchange for the exclusive license from Novimmune SA, Tiziana Life Sciences plc agreed to an upfront cash payment, milestone payments, and a royalty on future sales.

Make Enquiry Before Buying the Report: https://www.psmarketresearch.com/send-enquiry?enquiry-url=interleukin-6-inhibitors-therapeutics-pipeline 

Some of the key players developing drugs for the treatment of IL-6 inhibitors therapeutics include GlaxoSmithKline plc, Chugai Pharmaceutical Co., Ltd., Vitaeris Inc. and others.

IL-6 Inhibitors Therapeutics Pipeline Analysis

·         By Phase

·         By Molecule Type

·         By Route of Administration

·         By Company

Read More

Myelofibrosis Therapeutics Pipeline Analysis -Drug Profile, Top Industry Intelligence and Therapeutic Development

The study analysed that the therapeutics pipeline comprises of approximately 29 drug candidates in different stages of development. Myelofibrosis is a rare disorder in which excessive scar tissue gets formed in the bone marrow that impairs its ability to produce red blood cells. However, it is believed by researchers that myelofibrosis occurs due to the presence of abnormal red blood stem cells in the bone marrow. The abnormal blood stem cells produce mature cells that grow quickly and form scar tissue which leads to chronic inflammation.

Make Enquiry Before Buying the Report: https://www.psmarketresearch.com/send-enquiry?enquiry-url=myelofibrosis-therapeutics-pipeline-analysis 

Various companies, educational institutes and medical organization are collaborating for the development of therapeutics for the treatment of myelofibrosis. For instance, Geron Corporation and Janssen Pharmaceuticals, Inc. entered into a collaboration agreement, in which Geron Corporation granted an exclusive worldwide right to Janssen, for the development and commercialization of imetelstat for all human therapeutic uses, including hematologic myeloid malignancies.

Download Report Sample at: https://www.psmarketresearch.com/market-analysis/myelofibrosis-therapeutics-pipeline-analysis/report-sample

According to the research, there are several companies having drug candidates in their pipeline, using synthetic sources for the development of drugs for the treatment of myelofibrosis. Imetelstat is an oligonucleotide obtained from synthetic source that acts as telomerase inhibitor. 

Some of the key players developing drugs for myelofibrosis include CTI BioPharma Corporation, Geron Corporation, Gilead Sciences, Inc. and others.

Myelofibrosis Therapeutics Pipeline Analysis

·         By Phase

·         By Route of Administration

·         By Molecule Type

·         By Company

Contact:

P&S Market Research

347, 5th Ave. #1402

New York City, NY - 10016

Toll-free: +18887787886 (USA/Canada)

Email: enquiry@psmarketresearch.com

Web: https://www.psmarketresearch.com

Connect with us: LinkedIn | Twitter | Google + | Facebook

Read More

Myasthenia Gravis Therapeutics Pipeline Analysis- Clinical Trials & Results, Patent, Designation, Collaboration

The study analysed that the therapeutics pipeline comprises of approximately 19 drug candidates in different stages of development. Myasthenia gravis is a chronic autoimmune disorder that acts on neuromuscular junction and leads to the weakening of skeletal muscles. This causes loss of muscle control in moving the body parts, such as the movement of arms and legs, breathing, loss of eye movements, chewing, talking, and swallowing. The situation of the disease worsens after a period of activity and improves after a period of rest.

Browse Detailed Summary at: https://www.psmarketresearch.com/market-analysis/myasthenia-gravis-therapeutics-pipeline-analysis

Various companies, educational institutes and medical organizations are collaborating for the development of drugs for the treatment of this disease. For instance, Merck & Co., Inc. entered into a multi-targeted collaboration and license agreement with Ra Pharmaceuticals, Inc. to use the latter’s drug discovery technology platform for the development of orally available cyclic peptides for the treatment of myasthenia gravis.

Request Sample Pages: https://www.psmarketresearch.com/market-analysis/myasthenia-gravis-therapeutics-pipeline-analysis/report-sample

It has been observed that most of the drugs in the myasthenia gravis therapeutics pipeline, are being developed from the natural source. NT-1654 is a heparan sulfate proteoglycan, and is under development by Neurotune AG for the treatment of myasthenia gravis. The drug acts as a neuromuscular junction stimulator.

Pre-Purchase Enquiry: https://www.psmarketresearch.com/send-enquiry?enquiry-url=myasthenia-gravis-therapeutics-pipeline-analysis

Some of the key players developing drugs for the treatment of myasthenia gravis include Alexion Pharmaceuticals, Inc., CSL Behring LLC, Novartis AG and others.

Myasthenia gravis Therapeutics Pipeline Analysis

·         By Phase

·         By Molecule Type

·         By Route of Administration

·         By Company

Contact:

P&S Market Research

347, 5th Ave. #1402

New York City, NY - 10016

Toll-free: +18887787886 (USA/Canada)

Email: enquiry@psmarketresearch.com

Web: https://www.psmarketresearch.com

Connect with us: LinkedIn | Twitter | Google + | Facebook

Read More

OX-40 Receptor Agonist Therapeutics Pipeline Report Provides a Comprehensive Understanding of the Pipeline Activities Covering All Drug Candidates Under Various Stages of Development

The study analyzed that the OX-40 receptor agonist therapeutics pipeline comprises approximately nine drug candidates in different stages of development. OX-40 is a costimulatory receptor that binds to its only known ligand, OX-40L, initiating cellular signaling events required for full activation of T cells following their recognition of a foreign antigen. OX-40 agonists mimic the effect of OX-40L, and boost the OX-40 signaling, and thereby leads to the suppression of the anti-tumor immune response in cancer patients. OX-40 agonists in combination with checkpoint immunotherapies, surgical resection, and radiotherapy has demonstrated promising results for the treatment of cancer patients.

According to the research findings, most of the drug candidates of OX-40 receptor agonist therapeutics pipeline are being developed as a monoclonal antibody.

Download Report Sample at: https://www.psmarketresearch.com/market-analysis/ox40-receptor-agonist-therapeutics-pipeline/report-sample

Most of the companies are focused on developing their drug candidates as monoclonal antibodies in the OX-40 receptor agonist therapeutics pipeline. Monoclonal antibodies are homogenous and consistent. Also, they can be renewably generated once a suitable hybridoma is developed and are highly sensitive to small changes in both salt concentration and ph.

Make Enquiry Before Buying the Report: https://www.psmarketresearch.com/send-enquiry?enquiry-url=ox40-receptor-agonist-therapeutics-pipeline

In November 2015, GlaxoSmithKline plc and Merck & Co., Inc. entered into a collaboration to initiate the Phase I clinical trial designed to evaluate GSK3174998 as monotherapy in combination with Merck’s anti-PD-1 therapy, Keytruda (pembrolizumab). Some of the key players developing drugs as OX-40 receptor agonist for the treatment of various indications include MedImmune, LLC, Agenus Inc., Pfizer Inc., GlaxoSmithKline plc and others.

OX-40 Receptor Agonist Therapeutics Pipeline Analysis

·         By Phase

·         By Molecule Type

·         By Route of Administration

·         By Company

Contact:

P&S Market Research

347, 5th Ave. #1402

New York City, NY - 10016

Toll-free: +18887787886 (USA/Canada)

Email: enquiry@psmarketresearch.com

Web: https://www.psmarketresearch.com

Connect with us: LinkedIn | Twitter | Google + | Facebook

Read More